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What is quality of life (QOL)?
Quality of life includes psychological and social
functioning as well as physical functioning and incorpo-
rates positive aspects of well-being as well as negative
aspects of disease and infirmity. Health-related quality
of life (HRQL) often refers to a subset of specific QOL
endpoints which relates to the health of the patient.
HRQL is a relatively new outcome, which has been
considered for incorporation into randomized, controlled
clinical trials since the 1990s. Different methods have
been proposed for evaluating clinical interventions for
treatments of cancer in terms of their effects on disease-
related outcomes, social cost and quality of life. Patient
preference, too, has to be included in the evaluation.
This review aims to describe and to examine
different methods for assessing quality of life. Examples
are taken from the literature in order to show the
application to different cancer sites.
Why measure QOL?
The goals of cancer treatment and cancer prevention are
the extension of life expectancy and the improvement of
quality of life in the years prior to death. Usually,
outcomes of cancer treatment are evaluated in terms of
survival times. Although quality of life is often measured,
interpretation of these measurements in relation to
mortality is difficult. Survival analysis places each
individual into one of two categories: alive or dead.
Among those alive, all individuals are considered equi-
valent. Thus a patient confined to bed with severe sym-
ptoms is scored the same as someone who is active and
asymptomatic. Clinical oncology is always evolving. Newer
chemotherapeutic agents or regimens, and advances in
radiation technology are being examined in clinical trials
to improve survival. To a patient and a caregiver, the total
duration of being alive may not be most important. A new
treatment regimen may increase the three-year survival
from 11% to 23% [1], thus more than doubling the odds
of survival compared with survival after conventional
treatment but the new regimen may disrupt seriously
a patient's life or may cause significant treatment
morbidity and mortality.
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Quality of life has recently become an important outcome that has to be included and measured in prospective trials. There
are many different ways to measure quality of life. This review discusses in detail one method, the Quality-Adjusted Time
Without Symptoms or Toxicity (Q-TWiST). Variations of this method and its limitations, too are discussed in this review.
Practical examples of the use of this method in melanoma, breast and colon cancer in the literature are outlined. Its use also
lends itself to economic analysis of cost-effectiveness, which is increasing in importance as health care funding becomes more
scarce.
Parametr Q-TWiST (jakoÊç ˝ycia i prze˝ycie wolne od objawów chorobowych i toksycznoÊci) 
w ocenie jakoÊci ˝ycia chorych z nowotworem
W ostatnich latach jakoÊç ˝ycia sta∏a sie istotnym elementem, uwzgl´dnianym w toku oceny wyników badaƒ prospektywnych.
Istnieje wiele metod oceny jakoÊci ˝ycia. Niniejsza praca przedstawia dok∏adny opis jednej z nich – jakoÊci ˝ycia oraz prze˝y-
cia wolnego od objawów chorobowych i toksycznoÊci (Q-TwiST – Quality-Adjusted Time Without Symptoms or Toxicity).
Przedstawiamy równie˝ ró˝ne odmiany tej metody i jej ograniczenia oraz opisy jej zastosowania w praktyce u chorych z czer-
niakiem, rakiem piersi i rakiem jelita grubego. W pracy uwzgl´dniono równie˝ aspekty ekonomiczne, pozwalajàce na doko-
nywanie realnych oszcz´dnoÊci, co jest szczególnie istotne w dobie ograniczania nak∏adów na opiek´ zdrowotnà.
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More intensive regimens tend to have a negative
impact on QOL because of increased physical symptoms,
such as fatigue or the inconvenience of frequent attendan-
ces at the clinic, however, if the more intensive regimens
can be given over shorter periods of time, they may still be
worthwhile [2]. These facts are summarized in Table I.
Table I. Reasons why quality of life assessment is important
Different treatments may have similar survival
Treatment may improve survival but may have severe side effects
Treatment may have no effect on survival but may improve quality of
life
How to measure QOL?
Different instruments for measuring QOL include patient
or physician-administered questionnaires. Instruments
that detect different aspects of HRQL include health
profiles and utility measurements [3]. Health profiles are
highly responsive to change over time but are not easily
comparable between studies. On the other hand utility
measurements are not as responsive to change, but their
numerical values are more readily comparable between
studies. With the increasing number of multidimensional
instruments available for measurement of the quality of
life, investigators have to be careful that they select
instruments which are reliable and which have been
validated for incorporation into clinical trials. In addition,
investigators have to choose an instrument or instruments
which are best suited to detect the primary HRQL
outcomes which are of interest for a specific population.
A relatively new method for assessing the quality of
life during different health states is the Quality-Adjusted
Time Without Symptoms or Toxicity (Q-TWiST) statistic,
introduced by Glasziou, Simes and Gelber [4]. This
method combines toxicity, disease-free survival (DFS),
and overall survival (OS) in order to assess the impact
of treatments on the lives of patients. This methodology
has received positive reviews from clinicians as being
intuitive and useful and is used in many major clinical
trials [5-7]. Usually Q-TWiST is measured for two or more
treatment methods either prospectively or retrospectively.
OS and DFS data are also obtained. The duration of the
health states are obtained: toxicity (TOX) which may be
divided into acute short-term toxicity (TOX1) and
secondary toxicity (TOX2), time without symptom and
toxicity (TWiST) and relapse (REL).
Q-TWiST = (utox x TOX) + TWiST + (urel x REL)
where TOX, TWiST, and REL represent the durations
of these health state;
utox and urel are utility coefficients which reflect the values
of times in the health states TOX and REL, respectively.
The Q-TWiST method can be used in retrospective
data is seen in the author's previous publication [8]. Areas
under survival curves (AUC) can be retrospectively
weighted according to QOL coefficients [5]. The weights
assigned to each health state reflect their relative values in
terms of quality of life and allow the weights to vary in
a sensitivity analysis. The investigator can then combine
the results of individual trials in a meta-analysis, using
a multivariate regression model, in such a way that an
overall sensitivity analysis could be performed easily.
Individual patient-level data are not required in order to
perform this meta-analysis if the individual Q-TWiST
analysis result for each trial is available [9]. The goal of
such meta-analysis is to provide an aid to clinical decision-
making [5]. Murray et al reviewed aspects of the Q-
TWiST method for analyzing data from clinical trials,
and extended the method in order to accommodate
multiple treatment arms [6].
Cole presented a parametric methodology for per-
forming quality-of-life-adjusted survival analysis by use
of multivariate censored survival data [10]. Cole's method
represents a generalization of the nonparametric Q-
TWiST method. The event times correspond to tran-
sitions between states of health that differ in quality of
life. Each transition is governed by a competing risks
model in which the health states are the competing risks.
Overall survival is the sum of the amounts of time spent in
each health state. The proposed method consists of
defining a quality function that assigns a "score" to a life
having given health state transitions. It is a composite
measure of both quantity and quality of life. In general,
the quality function assigns a low value to a short life
with poor quality and a high value to a long life with good
quality. The results are useful for simultaneously eva-
luating treatments in terms of quantity and quality of life.
The Kaplan-Meier product-limit method is used to
estimate the mean duration of each health state [10].
These estimates provide the basis for quality-adjusted
survival analysis. The survival curves are modelled using
Cox's proportional hazards regression. Quality-adjusted
survival is estimated with given sets of covariate values.
This method permits the profiling of patients. Such results
are useful for investigating how prognostic factors affect
treatment benefits in terms of quality of life.
A General Health Policy Model is proposed in order
to adjust life expectancy for diminished quality of life,
which is measured using a standardized instrument known
as the Quality of Well-being (QWB) scale [11]. This
model expresses the effect of treatment in a unit known as
a Well-Year or a Quality Adjusted Life Year (QALY).
These units integrate side effects and benefits of treat-
ment by combining into a single value, mortality, mor-
bidity, and duration of each health state.
Using parametric models, another procedure for
projecting survival estimates beyond the follow-up limits
of a clinical trial has been developed [12]. The method
consists of fitting an appropriate parametric model to
the tail of a survival curve and then using the estimated
model in conjunction with the Kaplan-Meier product-
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limit estimate to produce a composite survival-function
estimator. This estimator is especially useful whenever
a parametric model is more easily fitted to the tail rather
than to the entire survival curve. The resulting projected
estimates of survival allow inferences to be made about
long-term treatment effects in clinical trials. Thus, survival
curves can be projected in order to estimate long-term
treatment effects on quality-of-life-adjusted survival. This
represents an extension of Q-TWiST, which evaluates
treatments in terms of both quantity and quality of life. In
a standard Q-TWiST analysis, the average time spent in
each of a number of health states, which differ in quality
of life, is estimated from clinical trial data. The health
states are weighted according to the quality of life
experienced, and the results are combined to produce an
estimate of quality-adjusted survival. Such estimates,
however, are restricted to the follow-up limit of the data.
The extrapolation methodology provides longer range
estimates of Q-TWiST.
The Gompertz extrapolation method is another
technique that has been proposed for evaluating survival
in cancer patients. The mathematical basis of the Q-
TWiST method relies on estimating the area under the
survival curve and partitioning this area into three
components with different levels of quality of life (pre-
sence of toxicity, presence of symptoms, absence of
symptoms and toxicity). The Gompertz method utilizes
a curve-fitting procedure in order to extrapolate the
survival curves to infinity. A published report [13] has
described a combined application of the Q-TWiST
method and the Gompertz approach called the "extra-
polated Q-TWiST" method, which allows one to conduct
a cost-utility analysis with the calculation of the cost per
QALY gained.
While economic evaluation has often included
quality of life within the concept of the QALY, deter-
mination of utilities within this concept has been highly
variable and the validity of the QALY as a concept has
been questioned. At the health policy decision-making
level, controversy persists over how much society should
pay for expansive new medical interventions and what
boundaries for allocation should be established. Much
work is still needed in order to improve comparability of
HRQL results and to incorporate these results into
clinical decision-making involving individual patients,
physicians and health policy makers.
What are the difficulties when measuring and
interpreting QOL?
What is meaningful to measure? Those responsible for
making treatment recommendations – such as clinicians
for individual patients, or health policy makers for groups
of patients – must weigh the expected benefits of
a treatment against its side effects, toxicity, inconvenience,
and cost. This process requires a reasonably accurate
understanding of the benefits and risks of alternative
treatments. Typically, clinicians' enthusiasm for inter-
vention decreases progressively as they see results
presented in terms of relative risk reduction, absolute
risk reduction, or the number needed to treat (NNT, the
reciprocal of the absolute risk reduction) [14].
Single anchor (or an independent measure) [15]
generally places great emphasis on a threshold that
demarcates trivial from small but important differences:
the "minimum important difference" or MID. One
popular definition of the MID is " the smallest difference
in score in the domain of interest which patients perceive
as beneficial and which would mandate, in the absence of
troublesome side effects and excessive cost, a change in
the patient's (health care) management" [16].
A naive approach assumes that if the mean diffe-
rence between treatment and control is less than the
MID, the treatment effect would be trivial, and if greater
than the MID, the treatment effect would be important.
This ignores the distribution of results. For example,
assume a MID of 0.5. A mean difference of 0.25 (trivial in
a naive interpretation) may be achieved if 25% of the
patients experience a benefit of 1.0 and 75% experience
no benefit. Such a situation results in an absolute
difference of 25% in the proportion of patients achieving
improvement and an NNT of 4 [17].
The problem becomes more complex when one
considers that patients may vary in the value they place on
a particular benefit. Furthermore, the same patient may
place a different value on the same benefit at different
times depending on the patient's circumstances.
In addition, missing data due to dropout of patients
may make interpretation of results difficult. Because the
patients who drop out are likely to be experiencing poorer
outcomes and thus poorer QOL, the methods of estima-
ting change over time need to be carefully chosen in order
to avoid bias. This is especially true when one is estima-
ting changes in groups of patients with very different rates
of dropouts [18]. One method is making the assumption
that the data are missing at random (MAR) and then
using all available observations; the results are obtained
using a standard procedure for multiple inputation [19,
20]. Another method is making the assumption that the
data are missing not at random (MNAR) and then relying
on auxiliary information such as the time to disease
progression and death. The rate of decline in QOL
depends on the length of survival (specifically, the natural
log of survival) [21]. Therefore when one reads an article,
one should take careful note of the analytical techniques
used for dealing with missing data, which cannot be
ignored.
When can Q-TWiST be applied?
Evaluation of adjuvant treatment method
Adjuvant therapy has been studied extensively for every
cancer. However, when adjuvant therapy is associated
with significant toxic effects, the question whether the
benefits of the treatment justify its quality-of-life costs
for the individual patient may be raised. Cole reported on
the use of the Q-TWiST concept in the individual decision
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process about adjuvant treatment for each patient with
resected cutaneous melanoma at high risk of recurrence
[9]. Overall, the interferon (IFN) alpha 2b group had
more quality-of-life-adjusted time than the observation
group, regardless of the relative valuations placed on
TOX and REL. This gain was significant (P < 0.05) for
patients who consider TOX to have a high relative value
and REL to have a low relative value. In contrast, the
quality-adjusted gain for IFN alpha 2b was present though
not statistically significant for patients who value TOX
about the same as REL. An analysis stratified according
to tumor burden indicated that the benefit of IFN alpha
2b was greatest in the node-positive strata. For patients
with high-risk melanoma, the optimal treatment for an
individual patient depends on the patient's tumor burden
and preferences about toxicity and disease relapse.
Another example is the data from a North Central
Cancer Treatment Group trial in which 204 patients with
poor-prognosis rectal cancer were randomly assigned to
receive either post-operative radiation therapy alone or
post-operative radiation therapy plus fluorouracil-based
chemotherapy [22]. A Q-TWiST analysis was used and
took into account freedom from symptomatic disease
and from early and late side effects of treatment.
The combined therapy reduced the risk of relapse
by 34% (95% confidence interval [CI] = 12%-50%;
P = 0.0016) and reduced the overall death rate by 29%
(95% CI =7%-45%; P = 0.025) in comparison with
adjuvant radiation therapy alone. In the 5 years following
assignment to treatment, despite an increase in the
amount of time that individuals spent with early and late
toxic effects, the Q-TWiST analysis indicated that the
combined therapy conferred significantly greater benefit
for a wide range of patient preferences about living with
the toxicity of treatment or the symptoms of overt disease.
Therefore, the use of combined chemotherapy and
radiation therapy as an adjuvant to surgery for patients
with resectable poor-prognosis rectal cancer is justified
because the improved outcome in terms of delayed
recurrence and increased survival more than balances
the time spent with early and late toxic effects.
Adjuvant chemotherapy for premenopausal breast
cancer patients with node-positive disease has been
studied in a meta-analysis [23]. Within 6 years of follow-
up, the benefits in terms of increased relapse-free and
overall survival balanced the costs in terms of acute toxic
side effects. This was true even for the extreme case in
which a zero value was assigned to all 6 months during
which patients might receive adjuvant cyclophosphamide,
methotrexate, and 5-flurouracil (CMF) chemotherapy.
Within 10 years of follow-up evaluation, treated patients
gained an average of 1.5 years of relapse-free survival
time, almost 1 year of overall survival time, and 1 year of
time without symptoms and toxicity.
An illustration of an adjuvant therapy that is not
worthwhile can be drawn from the meta-analysis of
quality-adjusted survival based on data from 3920 patients
aged 50 years or older with node-positive breast cancer
randomly assigned in nine trials that compared com-
bination chemotherapy plus tamoxifen with tamoxifen
alone. These nine trials were included in the worldwide
overview conducted by the early breast cancer trialists'
collaborative group (EBCTCG). The Q-TWiST method
was used to provide treatment comparisons incorporating
differences in quality of life associated with subjective
toxic effects of treatment and with symptoms of disease
relapse [24]. Within 7 years of follow-up the modest
benefit of increased relapse-free survival (RFS) and
overall survival (OS) for patients who received chemo-
therapy plus tamoxifen just balanced the costs in terms of
acute toxic side-effects. Chemotherapy-treated patients
gained an average of 5.4 months of RFS and 2 months of
OS (neither statistically significant), but had to receive
cytotoxic treatment for between 2 and 24 months to
achieve these gains. No values of preference weights for
time spent undergoing chemotherapy and for time after
relapse gave significantly more Q-TWiST with chemothe-
rapy plus tamoxifen than with tamoxifen alone. Thus
better selection of chemotherapy regimens, different
scheduling of chemotherapy and tamoxifen, and appro-
priate discriminative use of patient and tumor charac-
teristics should be studied further in order to increase
the therapeutic advantage of the combination treatment.
Comparison of different treatments
In prostate cancer, brachytherapy was compared to other
treatment modalities by health questionnaires: external
RT alone, external RT with brachytherapy, brachytherapy
alone, radical prostatectomy [25-27]. Generally, urinary
function was better in the brachytherapy group than in the
prostatectomy group because of less urinary incontinence
in the brachytherapy group. Brachytherapy group patients
had more irritative urinary symptoms and worse bowel
function than in healthy controls. Sexual function and
bother were worse in prostatectomy group patients and in
brachytherapy group patients than in healthy controls.
Physical function, bodily pain, urinary function, bother
and American Urological Association symptom index
scores improved with time after brachytherapy. Patients
who underwent brachytherapy after external beam
radiation performed worse in all general and disease
specific HRQOL domains compared with those who did
not undergo external beam radiation therapy before
brachytherapy. At an average of 7.5 months after treat-
ment, the general HRQOL domains of patients under-
going brachytherapy with and without prior external beam
radiation was similar to those of age matched controls,
although urinary, bowel and sexual problems were still
reported. These problems appeared to improve during
the first year after radiation treatment [27].
Evaluation of costs
The QOL concept leads itself to estimations of the costs
to the society of various treatments. Such cost estimation
was preformed by the National Cancer Institute on the
costs and benefits of combined levamisole and fluoro-
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uracil as adjuvant treatments for patients with stage III
colon cancer [28]. For a typical base-line patient, the
calculated cost-effectiveness of such adjuvant treatment is
a very favorable $2094 per year of life saved. Using
a variety of less favorable assumptions, the calculated
cost-effectiveness is still less than $5000 per year of life
saved, again this is a favorable value. QOL adjustments
have a negligible effect on the cost-effectiveness outcomes
in this study. Under a wide range of different reasonable
assumptions, adjuvant therapy for stage III colon cancer
appears to be a very cost-effective treatment [28].
Another example of evaluation of costs may be
obtained from the study of tamoxifen. This is the pre-
ferred adjuvant agent in postmenopausal women with
breast cancer. Patients with node-positive, estrogen
receptor-positive breast cancer have the most to gain
from adjuvant tamoxifen therapy. Data from a decision-
analysis model indicate that tamoxifen monotherapy has
a cost-utility ratio ($US6000 per additional QALY, in
1989 dollars) which is 5 to 6 times lower than that cited as
the cost-acceptability cut-off point in the US [29]. On the
other hand a combined regimen of adjuvant chemo-
therapy and tamoxifen has a high incremental cost-utility
ratio ($US58,000 per additional QALY, in 1989 dollars)
compared with the cost of no adjuvant therapy in
postmenopausal women with breast cancer.
What are the potential limitations of Q-TWiST?
Requirement for intelligent cooperative patients
Toxicity information has to be collected from patient-
completed diaries so that the actual duration of each
adverse event could be determined [30].
Scenarios when Q-TWiST may not apply too well
For patients who never achieve complete remission, the
time following disease relapse (REL) should be regarded
as zero.
One way of examining compromises between
quantity and quality of life is by combining them into
a single measure such as QALY. If censoring occurs, then
estimation of QALYs presents some difficulties. The Q-
TWiST approach is to define a series of health states and
to use a 'partitioned' survival analysis in order to calculate
the average time in each state, and then weight each state
according to its QOL to calculate QALYs. Such health-
state models are unhelpful, however, when the transitions
between health states are unclear or when these tran-
sitions do not adequately reflect variations in QOL
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